Form 4: United Therapeutics CFO Executes Stock Option Plan

CFO James Edgemond exercised 10,000 stock options and sold the resulting shares under a pre-arranged Rule 10b5-1 plan.

Summary

• CFO James Edgemond exercised 10,000 stock options at a strike price of $117.76.
• Following the exercise, the reporting person sold the 10,000 shares in multiple tranches at weighted average prices ranging from $557.85 to $566.12.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan established on October 31, 2025.
• The reporting person's direct beneficial ownership of common stock stands at 18,876 shares following these transactions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent standard executive compensation management.

Positives

• The transactions were executed under a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for corporate insiders to sell shares without triggering concerns regarding non-public information.

Negatives

• The transaction represents a reduction in the direct equity stake held by the CFO.

Risks

• None identified; this is a routine disclosure of insider trading activity.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a common practice among biotechnology executives to manage personal liquidity and diversify portfolios, and it generally does not signal a lack of confidence in the company's long-term prospects.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to conduct orderly divestments of equity compensation.

Stakeholder Impact

• Minimal impact on shareholders as the sale was conducted through a pre-arranged plan.

Key Dates

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, CFO, Stock Options, Rule 10b5-1